Showing results (141-150 of 187) with videos related to

Sort By:
Pageof 19
Cancer Discovery|December 6, 2011
A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatmentElizabeth A Platz, Srinivasan Yegnasubramanian, Jun O Liu, et al.
The Journal of Biological Chemistry|November 15, 2012
Polycomb group protein PHF1 regulates p53-dependent cell growth arrest and apoptosisYang Yang, Chenji Wang, Pingzhao Zhang, et al.
Hepatology (Baltimore, Md.)|August 5, 2010
Carbonyl reductase 1 as a novel target of (-)-epigallocatechin gallate against hepatocellular carcinomaWeixue Huang, Liya Ding, Qiang Huang, et al.
European Journal of Pharmacology|May 30, 2026
P-Glycoprotein-mediated efflux of rapaprotin-L dictates sensitivity of cancer cells to the inducer of 26S proteasome disassemblyQian Zhang, Thomas Asbell, A V Subba Rao, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
A whole-animal phenotypic drug screen identifies suppressors of atherogenic lipoproteinsDaniel J Kelpsch, Liyun Zhang, James H Thierer, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 13, 2011
A calcineurin-independent mechanism of angiogenesis inhibition by a nonimmunosuppressive cyclosporin A analogBenjamin A Nacev, Woon-Kai Low, Zhennian Huang, et al.
Molecular and Cellular Biology|October 31, 2007
RNA-binding proteins HuR and PTB promote the translation of hypoxia-inducible factor 1alphaStefanie Galbán, Yuki Kuwano, Rudolf Pullmann, et al.
Methods in Enzymology|October 10, 2007
Isolation and identification of eukaryotic initiation factor 4A as a molecular target for the marine natural product Pateamine AWoon-Kai Low, Yongjun Dang, Tilman Schneider-Poetsch, et al.
Cancer Biology & Therapy|February 5, 2013
Identification of cetrimonium bromide and irinotecan as compounds with synthetic lethality against NDRG1 deficient prostate cancer cellsMichel D Wissing, Janet Mendonca, Eunice Kim, et al.
The Journal of Clinical Investigation|October 7, 2009
Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activationHung-Chih Yang, Sifei Xing, Liang Shan, et al.
Pageof 19